REGENXBIO Inc. (NASDAQ:RGNX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET
Company Participants
Patrick Christmas - CLO
Curran Simpson - President and CEO
Steve Pakola - CMO
Vit Vasista - CFO
Conference Call Participants
Gena Wang - Barclays
Vikram Purohit - Morgan Stanley
Paul Choi - Goldman Sachs
Annabel Samimy - Stifel
C.J. Yeh - Leerink Partners
Luca Issi - RBC
Brian Skorney - Baird
Daniil Gataulin - Chardan Capital Markets
Operator
Welcome everyone to the Q2 2024 REGENXBIO's Earnings Conference Call. All lines have been placed on mute to prevent background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO. Please go ahead.
Patrick Christmas
Good afternoon and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the second quarter ended June 30th, 2024. The press release is available on our website at www.regenxbio.com.
Today's conference call will include forward-looking statements regarding our financial outlook, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties.
These risks are described in the risk factors and the management's discussion and analysis sections of REGENXBIO's annual report on Form 10-K for the full year ended December 31st, 2023, and comparable risk factors sections of REGENXBIO's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website.
Any information we provide on this conference call is provided only as of the date of this call, August 1st, 2024 and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events, or otherwise.
Please be advised that today's call is being recorded and webcast. In addition any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.
I would like to now turn the call over to Curran Simpson, President and CEO of REGENXBIO.